Impact of Demographics and Insurance Coverage on Schizophrenia Treatment and Healthcare Resource Utilization Within an Integrated Healthcare System

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2024 Oct 1

PMID 39351585

Authors

Sanghyuk Seo

Bridget E Healey

Ronae McLin

Naomi C Sacks

Carmela J Benson

Leslie Citrome

Affiliations

Soon will be listed here.

Abstract

Purpose: Little is known about the impact of health disparities on antipsychotic treatment and healthcare resource utilization (HRU) among patients with schizophrenia. The objective of this analysis is to examine treatment patterns and HRU by age, race/ethnicity, and insurance coverage among patients with schizophrenia in an integrated delivery network (IDN).

Patients And Methods: This cross-sectional study used electronic health record data from MedStar Health, an IDN in the Baltimore-Washington, DC, area. Patients were aged ≥18 years and had ≥2 outpatient encounters or ≥1 hospitalization with a diagnosis of schizophrenia between January 1, 2017 and March 31, 2021. Outcomes assessed included oral antipsychotic prescriptions, long-acting injectable antipsychotic (LAI) utilization, hospitalizations, emergency department (ED) visits, and outpatient visits. Analyses compared subgroups based on age, race/ethnicity (non-Hispanic Black, non-Hispanic White, and other), and type of insurance coverage at index (Medicare, Medicaid, and other) during 12 months of follow-up.

Results: A total of 78.1% of patients had ≥1 prescription for an antipsychotic and 69.1% received ≥1 second-generation antipsychotic. Second-generation long-acting injectables (SGA LAI) were utilized by 9.0% of patients, with the elderly and Medicaid beneficiaries having the lowest SGA LAI utilization. Overall, 61.7% of patients had ≥1 hospitalization, 56.4% had ≥1 outpatient visit, and 50.5% had ≥1 ED visit. Hospitalizations and ED visits were most common in those 18 to 24 years of age and in Medicaid beneficiaries, whereas outpatient visits were more common for the elderly and Medicare beneficiaries.

Conclusion: At the population level, the results indicate widespread underprescription/underutilization of antipsychotics that have been shown to improve clinical and economic outcomes in patients with schizophrenia, particularly SGA LAI. Within specific subpopulations, disparities in treatment selection and HRU were observed, suggesting the need for increased attention to at-risk groups to ensure consistent quality of care regardless of age, race/ethnicity, or insurance coverage.

References

Cahling L, Berntsson A, Broms G, Ohrmalm L . Perceptions and knowledge of antipsychotics among mental health professionals and patients. BJPsych Bull. 2017; 41(5):254-259. PMC: 5623883. DOI: 10.1192/pb.bp.116.055483. View

Bartels S, DiMilia P . Why serious mental illness should be designated a health disparity and the paradox of ethnicity. Lancet Psychiatry. 2017; 4(5):351-352. DOI: 10.1016/S2215-0366(17)30111-6. View

Iyer S, Banks N, Roy M, Tibbo P, Williams R, Manchanda R . A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives. Can J Psychiatry. 2013; 58(5 Suppl 1):23S-9S. DOI: 10.1177/088740341305805s04. View

Cheung P, Wiler J, Lowe R, Ginde A . National study of barriers to timely primary care and emergency department utilization among Medicaid beneficiaries. Ann Emerg Med. 2012; 60(1):4-10.e2. DOI: 10.1016/j.annemergmed.2012.01.035. View

Hardy M, Jackson C, Byrne J . Antipsychotic adherence and emergency department utilization among patients with schizophrenia. Schizophr Res. 2018; 201:347-351. DOI: 10.1016/j.schres.2018.06.006. View

Li P, Benson C, Geng Z, Seo S, Patel C, Doshi J . Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States. J Med Econ. 2023; 26(1):525-536. DOI: 10.1080/13696998.2023.2189859. View

Kishimoto T, Hagi K, Kurokawa S, Kane J, Correll C . Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021; 8(5):387-404. DOI: 10.1016/S2215-0366(21)00039-0. View

Hamilton J, Heads A, Meyer T, Desai P, Okusaga O, Cho R . Ethnic differences in the diagnosis of schizophrenia and mood disorders during admission to an academic safety-net psychiatric hospital. Psychiatry Res. 2018; 267:160-167. DOI: 10.1016/j.psychres.2018.05.043. View

Citrome L, Levine J, Allingham B . Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull. 1996; 32(3):321-6. View

10.

Normand S, Zelevinsky K, Finnerty M, Leckman-Westin E, Chen Q, Jeong J . Racial-Ethnic Disparities in Quality of Care Among Medicaid Beneficiaries With Schizophrenia. Psychiatr Serv. 2024; 75(10):969-978. DOI: 10.1176/appi.ps.20230564. View

11.

Fu A, Pesa J, Lakey S, Benson C . Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia. BMC Psychiatry. 2022; 22(1):250. PMC: 8994268. DOI: 10.1186/s12888-022-03895-2. View

12.

Barry S, Jarskog L, Xia K, Torpunuri R, Wu X, Zeng X . Racial Disparities in Clozapine Prescription Patterns Among Patients With Schizophrenia. Psychiatr Serv. 2024; 75(8):733-739. DOI: 10.1176/appi.ps.20230226. View

13.

Bareis N, Olfson M, Wall M, Stroup T . Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States. Psychiatr Serv. 2021; 73(5):492-500. PMC: 8964836. DOI: 10.1176/appi.ps.202000932. View

14.

Wilson A, Phillips J, Parisi A, Ishler K, Villodas M, Francis A . Patterns in Medicaid Coverage and Service Utilization Among People with Serious Mental Illnesses. Community Ment Health J. 2021; 58(4):729-739. DOI: 10.1007/s10597-021-00878-7. View

15.

van Walraven C, Austin P, Jennings A, Quan H, Forster A . A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009; 47(6):626-33. DOI: 10.1097/MLR.0b013e31819432e5. View

16.

Degan T, Kelly P, Robinson L, Deane F, Smith A . Health literacy of people living with mental illness or substance use disorders: A systematic review. Early Interv Psychiatry. 2020; 15(6):1454-1469. DOI: 10.1111/eip.13090. View

17.

Medina C, Akinkunmi A, Bland N, Velthorst E, Reichenberg A, Khachadourian V . Differences in schizophrenia treatments by race and ethnicity-analysis of electronic health records. Schizophrenia (Heidelb). 2024; 10(1):48. PMC: 11053048. DOI: 10.1038/s41537-024-00470-4. View

18.

Llorca P, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L . Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013; 13:340. PMC: 3898013. DOI: 10.1186/1471-244X-13-340. View

19.

Olfson M, Gerhard T, Huang C, Crystal S, Stroup T . Premature Mortality Among Adults With Schizophrenia in the United States. JAMA Psychiatry. 2015; 72(12):1172-81. DOI: 10.1001/jamapsychiatry.2015.1737. View

20.

Kadakia A, Catillon M, Fan Q, Williams G, Marden J, Anderson A . The Economic Burden of Schizophrenia in the United States. J Clin Psychiatry. 2022; 83(6). DOI: 10.4088/JCP.22m14458. View